ArticleBMC nephrology2025
Impact of red blood cell distribution width on response to HIF-PH inhibitor in improving anemia and clinical outcomes in patients with chronic kidney disease.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical feasibility and efficacy of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in patients with anemia in chronic kidney disease (CKD) remain uncertain. Red blood cell distribution width (RDW) may serve as a potential predictor for responsiveness to HIF-PH inhibitor therapy.
methodsConsecutive patients receiving HIF-PH inhibitors for anemia in CKD over three months were included. The predictive value of baseline RDW for the improvement in anemia in CKD, defined by the increase in hemoglobin levels to 10.0 g/dL or higher at within the first three months after initiation of therapy and the maintenance of that level thereafter, was assessed.
resultsA total of 106 patients were enrolled (median age 79 years; 57 males; 75 patients with heart failure; median estimated glomerular filtration rate 25.0 mL/min/1.73 m²; median hemoglobin level 9.3 g/dL). Among these, 84 patients met the primary outcome criteria. Baseline RDW-coefficient of variation (CV) ranged from 11.8% to 22.4%, with a median of 14.0%. Baseline RDW-CV independently predicted the primary outcome, with an odds ratio of 2.43 (95% confidence interval: 1.42–4.14, p < 0.01). The optimal cutoff value for predicting the primary outcome was identified as 13.7% (sensitivity 0.67, specificity 0.86). In addition, baseline RDW-CV levels were not significantly associated with overall and renal-related prognosis.
conclusionsBaseline RDW-CV independently predicts the therapeutic efficacy of mid-term HIF-PH inhibitor treatment for anemia in CKD.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.